JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.45 -0.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.45

Max

21.45

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -21M
Pardavimai	14M 54M
Pelno marža	-39.611
Darbuotojai	178
EBITDA	-3.8M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-3.62% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.2B
Ankstesnė atidarymo kaina	21.68
Ankstesnė uždarymo kaina	21.45

Naujienos nuotaikos

By Acuity

50%

175 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-01 21:36; UTC

Įsigijimai, susijungimai, perėmimai

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

2026-05-01 20:40; UTC

Įsigijimai, susijungimai, perėmimai

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

2026-05-01 18:37; UTC

Pagrindinės rinkos jėgos

Senseonic Shares Slide on Underwritten Offering Price

2026-05-01 16:46; UTC

Pagrindinės rinkos jėgos

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2026-05-01 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-01 20:42; UTC

Uždarbis

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

2026-05-01 19:33; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-01 19:33; UTC

Rinkos pokalbiai

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

2026-05-01 19:18; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

2026-05-01 19:13; UTC

Rinkos pokalbiai

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

2026-05-01 18:36; UTC

Uždarbis

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

2026-05-01 18:35; UTC

Uždarbis

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

2026-05-01 18:28; UTC

Uždarbis

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

2026-05-01 18:27; UTC

Rinkos pokalbiai

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

2026-05-01 18:14; UTC

Įsigijimai, susijungimai, perėmimai

Barclays Completes Acquisition of Best Egg

2026-05-01 18:04; UTC

Uždarbis

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

2026-05-01 17:43; UTC

Rinkos pokalbiai

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

2026-05-01 17:37; UTC

Rinkos pokalbiai

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

2026-05-01 17:30; UTC

Rinkos pokalbiai

Uždarbis

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

2026-05-01 17:28; UTC

Rinkos pokalbiai

Uždarbis

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

2026-05-01 17:21; UTC

Rinkos pokalbiai

Uždarbis

Apple Seen Absorbing Higher Memory Costs -- Market Talk

2026-05-01 17:19; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

2026-05-01 16:38; UTC

Rinkos pokalbiai

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

2026-05-01 16:23; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

2026-05-01 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-01 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-01 16:15; UTC

Uždarbis

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

2026-05-01 16:11; UTC

Rinkos pokalbiai

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

2026-05-01 16:04; UTC

Uždarbis

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-3.62% į apačią

12 mėnesių prognozė

Vidutinis 20.75 USD -3.62%

Aukščiausias 21.5 USD

Žemiausias 17 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

175 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.